← FDA DRUG APPROVALS

FDA ANDA · ANDA078873

METHYLPHENIDATE HYDROCHLORIDE

Sponsor: TEVA PHARMS

APPLICATION
ANDA078873
TYPE
ANDA
ORIGINAL APPROVAL
2012-07-19
LATEST ACTION
2022-10-06
ROUTE
ORAL
DOSAGE FORM
CAPSULE, EXTENDED RELEASE
MARKETING STATUS
Discontinued

Products

METHYLPHENIDATE HYDROCHLORIDEDiscontinued
METHYLPHENIDATE HYDROCHLORIDE 50MG · CAPSULE, EXTENDED RELEASE · ORAL
METHYLPHENIDATE HYDROCHLORIDEDiscontinued
METHYLPHENIDATE HYDROCHLORIDE 60MG · CAPSULE, EXTENDED RELEASE · ORAL
METHYLPHENIDATE HYDROCHLORIDEDiscontinued
METHYLPHENIDATE HYDROCHLORIDE 40MG · CAPSULE, EXTENDED RELEASE · ORAL

Approval history

2022-10-06Labeling · Supplement 4 · standardAP
2022-10-06Labeling · Supplement 13 · standardAP
2022-10-06Labeling · Supplement 9 · standardAP
2022-10-06Labeling · Supplement 14 · standardAP
2022-10-06Labeling · Supplement 6 · standardAP
2014-01-22Labeling · Supplement 3 · standardAP
2014-01-22Labeling · Supplement 1 · standardAP
2012-07-19OriginalReviewAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →